MRMarcelo Radisic

Marcelo Radisic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcelo Radisic has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Kidney Transplantation in Patients at Risk for Chagas Reactivation or Transmission: A Real‐World Cohort Study

    by Marcelo Victor Radisic, Natalia Pujato, Roxana del Grosso, Maria del Carmen Rial, Constanza Lopez‐Albizu, Javier Walther

    Background: Kidney transplant recipients in endemic areas are at risk of Trypanosoma cruzi reactivation or donor‐derived infection. Methods: We performed a retrospective study of all kidney transplants conducted between January 2018 and October 2023. Patients at risk for Chagas disease were defined as those with a seropositive donor and seronegative recipient (D+/R−), a seronegative donor and seropositive recipient (D−/R+), or a seropositive donor and a seropositive recipient (D+/R+). Screening was based on serology. Posttransplant monitoring included parasitemia detection using direct microscopy (Strout method) and quantitative polymerase chain reaction (qPCR). Outcomes included Chagas reactivation or primary infection, parasitemia dynamics, and clinical outcomes. Data on immunosuppression, rejection treatment, and graft and patient survival were also collected. Results: Among 954 kidney transplant recipients, 48 (5%) were identified as being at risk. Two patients were excluded (follow‐up at another center, n = 1; immediate graft loss due to hyperacute rejection, n = 1). qPCR detected parasitemia in 3/17 (18%) seropositive recipients and 2/28 (7%) recipients of organs from seropositive donors. (One of these two patients was non‐adherent to monitoring, and developed parasitemia detectable by the Strout method and clinical disease). Antitrypanosomal therapy was initiated in five patients (benznidazole, n = 4; nifurtimox, n = 1), including three R+ and two D+/R− cases, all achieving molecular clearance. During follow‐up (median: 29.77 months (range: 8.49–80.7), no patient developed further clinical manifestations after treatment. Conclusions: Molecular monitoring allows early detection of Chagas reactivation or transmission after kidney transplantation. Preemptive treatment triggered by parasitemia appears effective in preventing progression to clinical disease, with favorable long‐term outcomes.

  • Open Access

    Postoperative osteomyelitis caused by Rosenbergiella epipactidis: diagnostic challenges posed by a low-temperature–adapted environmental bacterium

    by Marcelo Victor Radisic, Marisa Almuzara, Claudia Beatriz Martinez, María Sol Haim, Tomás Poklepovich Caride, Carlos Vay

    Rosenbergiella epipactidis is an environmental Gram-negative bacterium associated with floral nectar and insect microbiota, with no prior reports of human infection. We report a postoperative osteoarticular infection in a 79-year-old man in which routine microbiological methods repeatedly failed to identify the causative organism. Despite inflammatory findings on Gram stain and histologically confirmed osteomyelitis, cultures incubated under standard conditions remained negative. A Gram-negative bacillus was recovered only after prolonged incubation at 25 °C from a deep surgical specimen. Identification by MALDI-TOF MS was inconclusive, whereas whole-genome sequencing established species identity (R. epipactidis; 95.9% average nucleotide identity). No acquired antimicrobial resistance genes were detected, and susceptibility testing performed at low incubation temperature guided effective therapy. This case underscores the importance of adapting culture conditions and incorporating genomic tools when investigating culture-negative postoperative infections.

  • Interesting case from Argentina: Kidney transplant recipient with skin lesions—A Latin American perspective

    by Marcelo Víctor Radisic, Guilherme Santoro Lopes, Alejandro Marcel Hasslocher‐Moreno, Emily M. Eichenberger, Victoria G. Hall, Natalia Rosana Pujato, Wanessa Trindade Clemente

    This is a case of a kidney transplant recipient who presented with skin lesions, low‐grade fevers, and pancytopenia 2 months after his transplant. image


  • Tuberculosis treatment without rifampin in kidney/kidney–pancreas transplantation: A case series report

    by Marcelo Victor Radisic, Natalia Rosana Pujato, Pablo Martin Bravo, Roxana Constanza del Grosso, Martin Hunter, Santiago Beltramino, Laura Linares González, María Lucía Cornet, Maria del Carmen Rial, Rosa Livia Franzini, et al.

    Background: The best approach to tuberculosis (TB) treatment in transplanted patients is still unknown. Current guidelines are based on evidence either extrapolated from other populations or observational. Rifampin‐containing regimens have strong pharmacokinetic interactions with immunosuppressive regimens, with high rates of organ dysfunction and ∼20% mortality. This report describes the results obtained using non‐rifampin‐containing regimens to treat confirmed TB in adult patients with kidney/kidney–pancreas transplantation.Methods: Retrospective data analysis from confirmed TB cases in adult kidney/kidney–pancreas transplant recipients (2006–2019), treated “de novo” with non‐rifampin‐containing regimens.Results: Fifty‐seven patients had confirmed TB. Thirty patients were treated “de novo” with non‐rifampin‐containing regimens. These patients’ mean age was 49.24 (±11.50) years. Induction immunosuppression was used in 22 patients. Maintenance immunosuppression was tacrolimus–mycophenolate–steroids in 13 (43%), sirolimus–mycophenolate–steroids in 6 (20%), and other immunosuppressive regimens in 11 (36%). Belatacept was used in four patients. TB localizations: pulmonary 43%; disseminated 23%; extrapulmonary 33%. Twenty‐seven (90%) patients completed treatment with isoniazid, ethambutol, and levofloxacin (12 months, 23; 9 months, 3; 6 months, 1); 12 of these patients also received pyrazinamide for the first 2 months and were cured with functioning grafts. One patient (3%) lost the graft while on treatment. Two patients (7%) died while on TB treatment. Median (range) follow‐up after completion of TB treatment was 32 (8–150) months. No TB relapses were observed.Conclusions: Results with non‐rifampin‐containing TB treatments in this case series were better (in terms of mortality and graft dysfunction) than those previously described with rifampin‐containing regimens in transplanted patients. image


    • 1 January 2021
      • Vol. 12  (3) , 42-47

    Kidney Transplantation in a Recipient with Positive RT-PCR for SARS-CoV-2

    by M. Radisic, J. C. Walther, G. Werber, N. Pujato, S. Beltramino, P. M. Bravo, A. Bello, M. Hunter

    When it is safe to proceed with transplantation after coronavirus disease 2019 (COVID-19) infection is still unknown. We describe the clinical course and management of immunosuppression in a patient with positive real-time polymerase chain reaction (RT-PCR) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a nasopharyngeal swab at the time of kidney transplantation, and with positive antibodies for SARS-CoV-2. The patient had no complications and was discharged with a functioning graft.

  • American trypanosomiasis (Chagas disease) in solid organ transplantation

    by Marcelo V. Radisic, Silvia A. Repetto

    This review addresses relevant aspects of Chagas disease in the solid organ transplantation setting. This trypanosomiasis was geographically restricted to America, but migration has turned Chagas disease into a global public health concern. Parasite persistence in chronically infected individuals entails the potential of transmission with organ donation and the potential for reactivation under immunosuppression. Prospective monitoring with real‐time PCR or direct methods for detection of parasitemia and treatment of documented episodes of transmission/ reactivation (rather than prophylactic treatment) is the recommended approach for managing patients at risk. Chagas disease is an important cause of terminal cardiomyopathy. Clinical results demonstrate that with adequate monitoring and treatment, patients with Chagas cardiomyopathy benefit from heart transplantation, with long‐term results even better than patients who underwent heart transplantation due to other conditions. Kidney and liver (and possibly other solid organs) transplantation can be safely performed in chronically infected patients with adequate management. Chronically infected patients are also suitable for organ donation (with the exception of the heart and intestines). Although reactivations and transmissions are observed, serious clinical disease is rare, and they are usually successfully managed with benznidazole or nifurtimox.